Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006342 · ClinicalTrials.gov registry record

Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor

A clinical trial of Lymphoma and Brain and Central Nervous System Tumors, sponsored by Duke University.

Completed
Registry status
19
Enrollment target
1
Study location

NCT00006342 is a study of Lymphoma and Brain and Central Nervous System Tumors that has completed, run by Duke University. The registered enrollment target is 19 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006342, a study of Lymphoma and Brain and Central Nervous System Tumors, has completed, sponsored by Duke University.

COMPLETED
Registry status
19 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Determination of genetic markers for leukemia or non-Hodgkin's lymphoma that is secondary to Hodgkin's disease and childhood brain tumors may help doctors to identify patients who are at risk for these cancers. PURPOSE: Clinical trial to determine the presence of certain genes in patients who are receiving treatment for Hodgkin's disease or childhood brain tumors.

Interventions

  • GENETIC mutation analysis
  • GENETIC chromosomal translocation analysis
  • GENETIC gene rearrangement analysis

Study Locations (1)

North Carolina

  • Duke Comprehensive Cancer Center - Durham

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 1997-01
Est. Completion 2001-01

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT00006342

The ClinicalTrials.gov registry entry for NCT00006342 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (96% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which mutation analysis is the first listed.

NCT00006342 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT00006342 about?

NCT00006342 is a clinical study titled "Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor". RATIONALE: Determination of genetic markers for leukemia or non-Hodgkin's lymphoma that is secondary to Hodgkin's disease and childhood brain tumors may help doctors to identify patients who are at risk for these cancers. PURPOSE: Clinical trial to determine the presence of certain genes in patient...

What is the current status of trial NCT00006342?

This trial is currently completed. The enrollment target is 19 participants. The study started on 1997-01. Estimated completion is 2001-01.

What conditions does trial NCT00006342 study?

This clinical trial studies the following conditions: Lymphoma, Brain and Central Nervous System Tumors.

What interventions are being tested in trial NCT00006342?

The interventions under investigation include: mutation analysis (GENETIC), chromosomal translocation analysis (GENETIC), gene rearrangement analysis (GENETIC).

Who is sponsoring clinical trial NCT00006342?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00006342 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.